Clinical Trials on Coagulation and Hemorrhagic Disorders in New Zealand

Total 16239 results

Novo Nordisk A/S

Completed

Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage

Acquired Bleeding Disorder | Intracerebral Haemorrhage

United States
Pfizer

Terminated

Study Evaluating The Safety Of Xyntha In Usual Care Settings

Hemophilia A

United States, New Zealand
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

Hemophilia A

Spain, Canada, United States, New Zealand, Italy, Poland
Stony Brook University

Completed

Effect of Chamomile Intake on Blood Coagulation Tests in Healthy Volunteers

Coagulation Disorder

United States
GlaxoSmithKline

Completed

Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment

Purpura, Thrombocytopaenic, Idiopathic

United States, Australia, New Zealand
Wyeth is now a wholly owned subsidiary of Pfizer

Withdrawn

Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A

Hemophilia A

Italy, United States, Netherlands, United Kingdom, Germany, New Zealand, Belgium, France
Stony Brook University

Completed

The Acute Effects of Chamomile Intake on Blood Coagulation Tests in Healthy Volunteers

Coagulation Disorder

United States
Rockefeller University
Weill Medical College of Cornell University

Completed

Assessment of Bleeding Symptoms in Normal Individuals Using a Comprehensive History Phenotyping Instrument

Bleeding Disorder

United States
University of Rochester

Terminated

Comparison Between Point of Care Device and Venous Blood International Normalized Ratio Measurements.

Blood Coagulation Disorder

United States
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale (Elevate)

Severe Hemophilia A

United States, Australia, New Zealand
Rutgers, The State University of New Jersey
Johns Hopkins University; National Heart, Lung, and Blood Institute (NHLBI); University... and other collaborators

Completed

Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures

Hemorrhage | Blood Coagulation Disorders

United States
Protalex, Inc.

Terminated

Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP

Idiopathic Thrombocytopenic Purpura (ITP)

Australia, New Zealand
Catalyst Biosciences

Completed

Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia

Hemophilia A

United States, Belgium, Hungary, Italy, New Zealand, South Africa, Turkey, United Kingdom
Novo Nordisk A/S

Completed

Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period (guardian 10)

Congenital Bleeding Disorder | Haemophilia A

India
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery

Hemophilia A

United States, New Zealand, Australia, Hungary, Sweden, Austria, Poland, Romania
New York Presbyterian Hospital

Completed

The Effect of Patient Counseling on Adolescent Hemophilia Patient Compliance With Bleeding Logs

Hemophilia A | Hemophilia B

United States
Novo Nordisk A/S

Completed

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage (FAST)

Acquired Bleeding Disorder | Intracerebral Haemorrhage

United States, Spain, Germany, Sweden, Netherlands, Austria, Belgium, Singapore, Taiwan, Israel, Italy, Denmark, Australia, Thailand, France, Norway, Croatia, Hong Kong, China, Canada, Switzerland, Brazil, Finland
Bayer

Terminated

Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors

Hemophilia A and B

Australia, United Kingdom, Taiwan, Japan, Korea, Republic of, Austria, Bulgaria, Hungary, Italy, France, New Zealand
Newark Beth Israel Medical Center
Genentech, Inc.

Not yet recruiting

Health-Related Quality of Life Outcomes and Bleeding Rates Among Patients With Severe Hemophilia A on Emicizumab (ML43518)

Hemophilia A

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A

Hemophilia A

Poland, Belgium, France, Italy, Spain, United States, Australia, Netherlands, New Zealand, Sweden, Germany, Finland, Hungary
Green Cross Corporation
Atlantic Research Group

Unknown

Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A

Hemophilia A

United States, Canada, New Zealand, Poland, Russian Federation, Ukraine, United Kingdom
Northwell Health
National Cancer Institute (NCI); University of California, San Diego

Completed

Ultrasonography in Hemophilic Joint Disease and Serum Markers

Hemophilia A | Hemophilia B | Hemarthroses

United States
Centers for Disease Control and Prevention

Completed

Treatment and Management of Women With Bleeding Disorders

Blood Coagulation Disorders | Blood Platelet Disorders | Menorrhagia | Hematologic Disease | Von Willebrand Disease

United States
St. Joseph's Healthcare Hamilton
McMaster University

Completed

Oral Vitamin K for Warfarin Associated Coagulopathy

Thrombosis | Bleeding | Coagulation

Canada, Singapore, United States, Italy
Novo Nordisk A/S

Completed

Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX (DOSE)

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

United States
Institute of Liver and Biliary Sciences, India

Completed

TEG (Thromboelastography) Based Versus Conventional Coagulation Parameters Based Correction of Coagulopathy in Non Variceal Bleed.

Non Variceal Bleed

India
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors (HAVEN 1)

Hemophilia A

Korea, Republic of, United States, France, Germany, Italy, South Africa, Spain, Japan, United Kingdom, Poland, Taiwan, Australia, Costa Rica, New Zealand
Baxalta now part of Shire

Completed

Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor

Hemophilia A | Hemophilia B | Hemophilia A or B With Inhibitors

Poland, United States, Bulgaria, Romania, Japan, Russian Federation, New Zealand, Croatia, Ukraine, Brazil
Green Cross Corporation
Atlantic Research Group

Unknown

Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A

Hemophilia A

United States
Pfizer

Terminated

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

Healthy | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Primary Immune Thrombocytopenia

Spain, United States, Belgium, United Kingdom, New Zealand
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B (PUPs B-LONG)

Hemophilia B

United States, Italy, Ireland, New Zealand, United Kingdom, Australia, Netherlands, Denmark, Poland, Sweden, France
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery

Hemophilia A

United States
Pfizer

Completed

Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII

Hemophilia A

United States, Argentina, Austria, Colombia, Croatia, Jordan, Mexico, New Zealand, Oman, Peru, Poland, Romania, Turkey
Bayer

Completed

Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies (PARkER)

Hemophilia A

United States
Weill Medical College of Cornell University

Withdrawn

Collection of Blood in Normal Subjects and Subjects With Von Willebrand Disease (VWD)

Von Willebrand Disease

United States
Novo Nordisk A/S

Completed

Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A (pathfinder™2)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Denmark, Netherlands, Sweden, Spain, Germany, Switzerland, Taiwan, Japan, United Kingdom, Croatia, Italy, Malaysia, Brazil, Australia, Hungary, Israel, Turkey, Puerto Rico, Norway, Korea, Republic of, Bulgaria, Russian...
Grifols Therapeutics LLC
Instituto Grifols, S.A.

Completed

Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital Afibrinogenemia (IG0902)

Congenital Afibrinogenemia

India, United States, Italy, Lebanon
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A (pathfinder™6)

Congenital Bleeding Disorder | Haemophilia A

United States, Spain, Australia, France, Thailand, Italy, Malaysia, Austria, Greece, Japan, Taiwan, Canada, Israel, Algeria, Argentina, Bulgaria, Germany, Romania
Mary M. Gooley Hemophilia Center

Completed

The Use of Cyclokapron for Treatment and Management of Women With Bleeding Disorders

Hemophilia | vonWillebrand Disease | Platelet Coagulation Disorders

United States
Montefiore Medical Center
Genentech, Inc.

Not yet recruiting

Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A

Hemophilia A

United States
Healthcare Innovation Technology Lab
Bayer

Unknown

Hemophilia Mobile App Usability Pilot

Hemophilia

United States
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Completed

A Study of ADVATE in People With Hemophilia A in India

Hemophilia A

India
Novo Nordisk A/S

Terminated

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation

Acquired Bleeding Disorder | Bleeding During/Following Surgery

United States
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...
Sintesi Research Srl

Unknown

Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients (ITI)

Hemophilia A

India, Egypt
Octapharma

Completed

Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A

Hemophilia A

United States, Germany, Bulgaria
Tulane University
Genentech, Inc.

Recruiting

Factor IX as Adjunctive Therapy to Emicizumab (EMIX)

Hemophilia A

United States
CSL Behring

Recruiting

An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B (IX-TEND 4001)

Hemophilia B

United States
Baxalta now part of Shire

Completed

Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

Hemophilia A

United States
Genentech, Inc.

Terminated

Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures

Hemophilia A

United States
Eisai Inc.

Completed

Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)

Immune Thrombocytopenia | Chronic Thrombocytopenia

Poland, Ukraine, Belgium, Bulgaria, South Africa, Netherlands, New Zealand, Singapore, Australia, Slovakia, Czechia

Clinical Trials on Coagulation and Hemorrhagic Disorders in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations